Edwards Lifesciences (EW) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Edwards Lifesciences (EW) shares decline as growth disappoints investors
July 27, 2023 12:19 PM EDTShares of Edwards Lifesciences (NYSE: EW) declined after it reported second quarter results. Despite solid earnings per share and revenue, growth rates disappointed investors.
Edwards Lifesciences reported second quarter sales that were slightly above consensus at $1.53 billion. At $0.66, EPS topped consensus by a penny.
The company expects full year 2023 sales to be between $5.9 billion and $6.1 billion. For the year, the company expects transcatheter aortic... More
